MCA logo
MCA logo



FDA approves lenacapavir (Sunleca®) in heavily pre-treated adults with multi-drug resistant HIV-1 infection

Lenacapavir, HIV
Lenacapavir (Sunleca®), a first-in-class long-acting HIV-1 capsid function inhibitor, was approved by the FDA in December 2022

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

hay fever steroid
Hay Fever Tea Sold in Japan Found to Contain Steroid

Hay fever is a common condition affecting millions worldwide, causing symptoms such as sneezing, itching, and a runny nose. While there are many over-the-counter remedies available, some individuals turn to alternative treatments such as herbal teas. Recently, a Japanese health tea, advertised as “effective for hay fever,” has been found to contain the steroid dexamethasone, a potentially harmful substance.

Read More »
Fibromyalgia: The Under Diagnosed Danger

This article discusses the under-diagnosed danger of fibromyalgia, a chronic pain condition that affects millions of people worldwide. Learn about its symptoms, risk factors, and the importance of early diagnosis and treatment in managing the condition.

Read More »